Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Guillaume CartronEmmanuel BachyHerve TillyNicolas DaguindauGian-Matteo PicaFontanet BijouChristiane MounierAline ClavertGandhi Laurent DamajBorhane SlamaRené-Olivier CasasnovasRoch HouotKrimo BouabdallahDavid SibonOlivier FitoussiNadine MorineauCharles HerbauxThomas GastinneLuc-Matthieu ForneckerCorinne HaiounVincent LaunayCarla AraujoOmar BenbrahimLaurence SanhesRemy GressinHugo GonzalezJudith TrotmanDavid TernantLuc XerriKarin TarteDelphine PrangerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
SC rituximab improves PFS for patients with low-tumor burden FL when used in induction followed by short maintenance. High rituximab exposure during the first 3 months after treatment initiation is, however, the only parameter influencing patient outcomes.